NeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology

Reuters

2025/07/30

<a href="https://laohu8.com/S/NEO">NeoGenomics</a> Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology

NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer™ LBx, a new blood-based comprehensive genomic profiling (CGP) test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730287071) on July 30, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555432060"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555432060\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555432060?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-30 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555432060","market":"us","top_or_hot":-1,"title":"NeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer™ LBx, a new blood-based comprehensive genomic profiling (CGP) test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730287071) on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-30 19:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer™ LBx, a new blood-based comprehensive genomic profiling (CGP) test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730287071) on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL9LvXWC:1","article_id":"2555432060","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555432060","pubTimestamp":1753873516,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer LBx, a new blood-based comprehensive genomic profiling  test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","NEO":"NeoGenomics","BK4196":"保健护理服务","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV"},"translate_title":"NeoGenomics Inc.推出PanTracer LBx：一种用于肿瘤学全面基因组图谱的新型液体活检测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":0.9},"content_text":"NeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology\n    \n\n        NeoGenomics Inc., a prominent provider of oncology diagnostic solutions, has announced the launch of NEO PanTracer™ LBx, a new blood-based comprehensive genomic profiling (CGP) test. This ctDNA-based test is designed to enhance access to genomic profiling for patients with advanced solid tumors, particularly when tissue samples are limited or unavailable. The PanTracer LBx test aims to support therapy selection, trial matching, and longitudinal monitoring. It offers a seven-day turnaround time and analyzes over 500 genes, providing timely and actionable insights. This launch is part of NeoGenomics' strategic expansion into the liquid biopsy market, which is valued at $3-5 billion, and underscores the company's commitment to advancing precision oncology. Results of the test's impact and efficacy have not been specified as presented or scheduled for future presentation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730287071) on July 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}